Medicine Access Programmes: what do patients think - a patient-reported outcome study on ribociclib in metastatic breast cancer in Australia.

Medication Access Programme patient‐reported outcome quality of life

Journal

Internal medicine journal
ISSN: 1445-5994
Titre abrégé: Intern Med J
Pays: Australia
ID NLM: 101092952

Informations de publication

Date de publication:
28 Oct 2024
Historique:
received: 16 02 2024
accepted: 06 09 2024
medline: 28 10 2024
pubmed: 28 10 2024
entrez: 28 10 2024
Statut: aheadofprint

Résumé

This study evaluated patient-reported outcomes (PROs) of Medicine Access Programmes (MAPs) for Australian metastatic breast cancer patients on ribociclib. Limited patient awareness of MAP enrolment was identified, emphasising the need for improved education and consent processes. Most patients expressed gratitude for accessing non-funded medications and perceived enhanced medication adherence as a key benefit. Integrating PRO data with real-world registry data provides comprehensive insight for future MAP development.

Identifiants

DOI: 10.1111/imj.16536 PMID: 39467087
pubmed: 39467087
doi: 10.1111/imj.16536
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024 Royal Australasian College of Physicians.

Références

Vivot A, Jacot J, Zeitoun JD, Ravaud P, Créquit P, Porcher R. Clinical benefit, price and approval characteristics of FDA‐approved new drugs for treating advanced solid cancer, 2000–2015. Ann Oncol 2017; 28: 1111–1116.
Wong V, de Boer R, Baron‐Hay S, Blum R, Boyle F, Chua S et al. Real‐world outcomes of ribociclib and aromatase inhibitor use in first line hormone receptor positive, HER2‐negative metastatic breast cancer. Clin Breast Cancer 2022; 22: 792–800.
Pharmaceutical Benefits Scheme. Ribociclib with an aromatase inhibitor for metastatic breast cancer – Pharmaceutical Benefits Scheme [Internet]. Pharmaceutical Benefits Scheme; 2020 [cited 2024 Jan 3]. Available from URL: https://www.pbs.gov.au/info/industry/listing/participants/public-release-docs/ribociclib
Grover P, Babar ZUD, Oehmen R, Vitry A. Medicines access programmes to cancer medicines in Australia and New Zealand: an exploratory study. Health Policy 2018; 122: 243–249.
Lewis JRR, Lipworth W, Kerridge I, Doran E. Dilemmas in the compassionate supply of investigational cancer drugs. Intern Med J 2014; 44: 841–845.
Council of Australian Therapeutic Advisory Groups. Managing Medicines Access Programmes. Guiding principles for the governance of Medicines Access Programmes in Australian hospitals. Version 2. Council of Australian Therapeutic Advisory Groups; 2018.
Australian Rare Cancer Portal. Introducing Medicines Access Portal [Internet]. ARC Portal; 2022 [cited 2024 Jan 3]. Available from URL: https://www.arcportal.org.au/news/58/introducing-medicines-access-portal
Medicines Australia. MAP offers new online pathway for accessing cancer treatments – Medicines Australia [Internet]. Medicines Australia; 2022 [cited 2024 Jan 3]. Available from URL: https://www.medicinesaustralia.com.au/media-release/map-offers-new-online-pathway-for-accessing-cancer-treatments

Auteurs

Natasha Yap (N)

Department of General Medicine, Royal Melbourne Hospital, Melbourne, Victoria, Australia.
ORCID: 0009-0007-6677-573X

Vanessa Wong (V)

Gibbs Labs, Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
Department of Medical Oncology, Western Health, Melbourne, Victoria, Australia.
ORCID: 0000-0002-4323-8786

Catherine Morton (C)

Gibbs Labs, Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.

Richard de Boer (R)

Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
St Vincent's Private Hospital, Melbourne, Victoria, Australia.

Sally Baron-Hay (S)

Department of Medical Oncology, Northern Cancer Institute, Sydney, New South Wales, Australia.

Robert Blum (R)

Department of Medical Oncology, Bendigo Health, Bendigo, Victoria, Australia.

Benjamin Forster (B)

Department of Medical Oncology, Mater Hospital, Sydney, New South Wales, Australia.

Susan Chua (S)

Department of Medical Oncology, Eastern Health, Melbourne, Victoria, Australia.

Kerrie Clarke (K)

Department of Medical Oncology, Albury Wodonga Regional Cancer Centre, Albury, New South Wales, Australia.

Katharine Cuff (K)

Department of Medical Oncology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.

Michael Green (M)

Epworth Freemasons, Melbourne, Victoria, Australia.

Elgene Lim (E)

Department of Medical Oncology, Kinghorn Cancer Centre, Sydney, New South Wales, Australia.

Kelly Mok (K)

Department of Medical Oncology, Liverpool Hospital, Sydney, New South Wales, Australia.

Louise Nott (L)

Department of Medical Oncology, Royal Hobart Hospital, Hobart, Tasmania, Australia.

Michelle Nottage (M)

Department of Medical Oncology, Royal Brisbane Hospital, Brisbane, Queensland, Australia.

Ali Tafreshi (A)

Department of Medical Oncology, Wollongong Private Hospital, Wollongong, New South Wales, Australia.

Daphne Tsoi (D)

Department of Medical Oncology, St John of God Hospital, Perth, Western Australia, Australia.

Anthony Uccellini (A)

Olivia Newton-John Cancer and Wellness Centre, Austin Health, Melbourne, Victoria, Australia.

Peter Gibbs (P)

Gibbs Labs, Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
Department of Medical Oncology, Western Health, Melbourne, Victoria, Australia.

Sheau Wen Lok (SW)

Gibbs Labs, Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
ORCID: 0000-0002-9919-1665

Classifications MeSH